|
1
|
Amin MB, Ro JY, el-Sharkawy T, Lee KM,
Troncoso P, Silva EG, Ordóñez NG and Ayala AG: Micropapillary
variant of transitional cell carcinoma of the urinary bladder.
Histologic pattern resembling ovarian papillary serous carcinoma.
Am J Surg Pathol. 18:1224–1232. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Amin MB, Tamboli P, Merchant SH, Ordóñez
NG, Ro J, Ayala AG and Ro JY: Micropapillary component in lung
adenocarcinoma: A distinctive histologic feature with possible
prognostic significance. Am J Surg Pathol. 26:358–364. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Luna-Moré S, Gonzalez B, Acedo C, Rodrigo
I and Luna C: Invasive micropapillary carcinoma of the breast. A
new special type of invasive mammary carcinoma. Pathol Res Pract.
190:668–674. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nagao T, Gaffey TA, Visscher DW, Kay PA,
Minato H, Serizawa H and Lewis JE: Invasive micropapillary salivary
duct carcinoma: A distinct histologic variant with biologic
significance. Am J Surg Pathol. 28:319–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sakamoto K, Watanabe M, De La Cruz C,
Honda H, Ise H, Mitsui K, Namiki K, Mikami Y, Moriya T and Sasano
H: Primary invasive micropapillary carcinoma of the colon.
Histopathology. 47:479–484. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith Sehdev AE, Sehdev PS and Kurman RJ:
Noninvasive and invasive micropapillary (low-grade) serous
carcinoma of the ovary: A clinicopathologic analysis of 135 cases.
Am J Surg Pathol. 27:725–736. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nassar H, Pansare V, Zhang H, Che M, Sakr
W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J and Adsay V:
Pathogenesis of invasive micropapillary carcinoma: Role of MUC1
glycoprotein. Mod Pathol. 17:1045–1050. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nassar H: Carcinomas with micropapillary
morphology: Clinical significance and current concepts. Adv Anat
Pathol. 11:297–303. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sangoi AR, Beck AH, Amin MB, Cheng L,
Epstein JI, Hansel DE, Iczkowski KA, Lopez-Beltran A, Oliva E,
Paner GP, et al: Interobserver reproducibility in the diagnosis of
invasive micropapillary carcinoma of the urinary tract among
urologic pathologists. Am J Surg Pathol. 34:1367–1376. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamat AM, Dinney CP, Gee JR, Grossman HB,
Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL and Pisters LL:
Micropapillary bladder cancer: A review of the University of Texas
M. D. Anderson Cancer Center experience with 100 consecutive
patients. Cancer. 110:62–67. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
López JI, Elorriaga K, Imaz I and Bilbao
FJ: Micropapillary transitional cell carcinoma of the urinary
bladder. Histopathology. 34:561–562. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Compérat E, Roupret M, Yaxley J, Reynolds
J, Varinot J, Ouzaïd I, Cussenot O and Samaratunga H:
Micropapillary urothelial carcinoma of the urinary bladder: A
clinicopathological analysis of 72 cases. Pathology. 42:650–654.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ross JS, Wang K, Gay LM, Al-Rohil RN,
Nazeer T, Sheehan CE, Jennings TA, Otto GA, Donahue A, He J, et al:
A high frequency of activating extracellular domain ERBB2 (HER2)
mutation in micropapillary urothelial carcinoma. Clin Cancer Res.
20:68–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Perepletchikov AM and Parwani AV:
Micropapillary urothelial carcinoma: Clinico-pathologic review.
Pathol Res Pract. 205:807–810. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Johansson SL, Borghede G and Holmäng S:
Micropapillary bladder carcinoma: A clinicopathological study of 20
cases. J Urol. 161:1798–1802. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Paterakos M, Watkin WG, Edgerton SM, Moore
DH II and Thor AD: Invasive micropapillary carcinoma of the breast:
A prognostic study. Hum Pathol. 30:1459–1463. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Marchiò C, Iravani M, Natrajan R, Lambros
MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S,
et al: Genomic and immunophenotypical characterization of pure
micropapillary carcinomas of the breast. J Pathol. 215:398–410.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weigelt B, Horlings HM, Kreike B, Hayes
MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't
Veer LJ and Peterse JL: Refinement of breast cancer classification
by molecular characterization of histological special types. J
Pathol. 216:141–150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lotan TL, Ye H, Melamed J, Wu XR, Shih IeM
and Epstein JI: Immunohistochemical panel to identify the primary
site of invasive micropapillary carcinoma. Am J Surg Pathol.
33:1037–1041. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Trabelsi A, Stita W, Soumaya R, Mestiri S,
Jaidene M, Mokni M and Korbi S: Micropapillary carcinoma of the
urinary bladder: A case report and review of the literature. Can
Urol Assoc J. 2:540–542. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alkibay T, Sözen S, Gürocak S, Işik Gönül
I, Poyraz A and Ure I: Micropapillary pattern in urothelial
carcinoma: A clinicopathological analysis. Urol Int. 83:300–305.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Watts KE and Hansel DE: Emerging concepts
in micropapillary urothelial carcinoma. Adv Anat Pathol.
17:182–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samaratunga H and Delahunt B: Recently
described and unusual variants of urothelial carcinoma of the
urinary bladder. Pathology. 44:407–418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alvarado-Cabrero I, Sierra-Santiesteban
FI, Mantilla-Morales A and Hernández-Hernandez DM: Micropapillary
carcinoma of the urothelial tract. A clinicopathologic study of 38
cases. Ann Diagn Pathol. 9:1–5. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Heudel P, El Karak F, Ismaili N, Droz JP
and Flechon A: Micropapillary bladder cancer: A review of Léon
Bérard Cancer Center experience. BMC Urol. 9:52009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lopez-Beltran A, Cheng L, Raspollini MR,
Canas-Marques R, Scarpelli M, Cimadamore A, Gasparrini S and
Montironi R: Variants of bladder cancer: The pathologist's point of
view. Eur Urol Suppl. 16:210–222. 2017. View Article : Google Scholar
|
|
27
|
Sakuma T, Furuta M, Mimura A, Tanigawa N,
Takamizu R and Kawano K: Urine cytology of micropapillary carcinoma
of the urinary bladder. Diagn Cytopathol. 39:852–856. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maranchie JK, Bouyounes BT, Zhang PL,
O'Donnell MA, Summerhayes IC and DeWolf WC: Clinical and
pathological characteristics of micropapillary transitional cell
carcinoma: A highly aggressive variant. J Urol. 163:748–751. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Amin A and Epstein JI: Noninvasive
micropapillary urothelial carcinoma: A clinicopathologic study of
18 cases. Hum Pathol. 43:2124–2128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moch H, Humphrey PA, Ulbright TM and
Reuter V: WHO Classification of Tumors of the Urinary System and
Male Genital Organs. 8. 4th. IARC Press; Lyon, France: 2016
|
|
31
|
Samaratunga H and Khoo K: Micropapillary
variant of urothelial carcinoma of the urinary bladder; a
clinicopathological and immunohistochemical study. Histopathology.
45:55–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Willis DL, Fernandez MI, Dickstein RJ,
Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA,
Grossman HB, et al: Clinical outcomes of cT1 micropapillary bladder
cancer. J Urol. 193:1129–1134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang JK, Boorjian SA, Cheville JC, Kim SP,
Tarrell RF, Thapa P and Frank I: Outcomes following radical
cystectomy for micropapillary bladder cancer versus pure urothelial
carcinoma: A matched cohort analysis. World J Urol. 30:801–806.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ching CB, Amin MB, Tubbs RR, Elson P,
Platt E, Dreicer R, Fergany A and Hansel DE: HER2 gene
amplification occurs frequently in the micropapillary variant of
urothelial carcinoma: Analysis by dual-color in situ hybridization.
Mod Pathol. 24:1111–1119. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schneider SA, Sukov WR, Frank I, Boorjian
SA, Costello BA, Tarrell RF, Thapa P, Houston Thompson R, Tollefson
MK, Jeffrey Karnes R, et al: Outcome of patients with
micropapillary urothelial carcinoma following radical cystectomy:
ERBB2 (HER2) amplification identifies patients with poor outcome.
Mod Pathol. 27:758–764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Patriarca C and Giunta P: Invasive
micropapillary carcinoma: Beyond the borders. Am J Surg Pathol.
35:311–312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Amin MB: Histological variants of
urothelial carcinoma: Diagnostic, therapeutic and prognostic
implications. Mod Pathol. 22 Suppl 2:S96–S118. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Humphrey PA: Micropapillary urothelial
carcinoma of the urinary tract. J Urol. 186:1071–1072. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lopez-Beltran A, Montironi R, Blanca A and
Cheng L: Invasive micropapillary urothelial carcinoma of the
bladder. Hum Pathol. 41:1159–1164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Oh YL and Kim KR: Micropapillary variant
of transitional cell carcinoma of the ureter. Pathol Int. 50:52–56.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Perez-Montiel D, Wakely PE, Hes O, Michal
M and Suster S: High-grade urothelial carcinoma of the renal
pelvis: Clinicopathologic study of 108 cases with emphasis on
unusual morphologic variants. Mod Pathol. 19:494–503. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kuroda N, Tamura M, Ohara M, Hirouchi T,
Mizuno K and Miyazaki E: Invasive micropapillary carcinoma of the
urinary bladder: An immunohistochemical study of neoplastic and
stromal cells. Int J Urol. 13:1015–1018. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhang HSR, Ali-Fehmi R and Bianco F:
Characteristic immunohistochemical profiles and aggressive behavior
of micropapillary and other histological variants and subtypes of
urothelial carcinoma. Mod Pathol. 17 (Suppl 1):186A(782). 2014.
|
|
44
|
Ohtsuki Y, Kuroda N, Umeoka T, Watanabe R,
Ochi K, Okada Y, Lee GH and Furihata M: KL-6 is another useful
marker in assessing a micropapillary pattern in carcinomas of the
breast and urinary bladder, but not the colon. Med Mol Morphol.
42:123–127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sangoi AR, Higgins JP, Rouse RV, Schneider
AG and McKenney JK: Immunohistochemical comparison of MUC1, CA125,
and Her2Neu in invasive micropapillary carcinoma of the urinary
tract and typical invasive urothelial carcinoma with retraction
artifact. Mod Pathol. 22:660–667. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Guo CC, Dadhania V, Zhang L, Majewski T,
Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, et
al: Gene expression profile of the clinically aggressive
micropapillary variant of bladder cancer. Eur Urol. 70:611–620.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Nishizawa K, Kobayashi T, Mitsumori K, Ide
Y, Watanabe J and Ogura K: Micropapillary bladder cancer. Int J
Urol. 12:506–508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kwon GY and Ro JY: Micropapillary variant
of urothelial carcinoma. Adv Urol. 2011:2171532011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Compérat E, Roupret M, Conort P,
Chartier-Kastler E, Bitker MO, Richard F, Capron F, Haertig A,
Cussenot O and Camparo P: Aurora-A/STK-15 is differentially
expressed in the micropapillary variant of bladder cancer. Urol
Int. 82:312–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sen S, Zhou H, Zhang RD, Yoon DS,
Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC,
et al: Amplification/overexpression of a mitotic kinase gene in
human bladder cancer. J Natl Cancer Inst. 94:1320–1329. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cormio L, Tolve I, Annese P, Saracino A,
Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP and
Carrieri G: Retinoblastoma protein expression predicts response to
bacillus Calmette-Guérin immunotherapy in patients with T1G3
bladder cancer. Urol Oncol. 28:285–289. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cormio L, Tolve I, Annese P, Saracino A,
Zamparese R, Sanguedolce F, Bufo P, Battaglia M, Selvaggi FP and
Carrieri G: Altered p53 and pRb expression is predictive of
response to BCG treatment in T1G3 bladder cancer. Anticancer Res.
29:4201–4204. 2009.PubMed/NCBI
|
|
53
|
Meeks JJ, Taylor JM, Matsushita K, Herr
HW, Donat SM, Bochner BH and Dalbagni G: Pathological response to
neoadjuvant chemotherapy for muscle-invasive micropapillary bladder
cancer. BJU Int. 111:E325–E330. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kamat AM, Gee JR, Dinney CP, Grossman HB,
Swanson DA, Millikan RE, Detry MA, Robinson TL and Pisters LL: The
case for early cystectomy in the treatment of nonmuscle invasive
micropapillary bladder carcinoma. J Urol. 175:881–885. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhai QJ, Black J, Ayala AG and Ro JY:
Histologic variants of infiltrating urothelial carcinoma. Arch
Pathol Lab Med. 131:1244–1256. 2007.PubMed/NCBI
|
|
56
|
Black PC, Brown GA and Dinney CPN: The
impact of variant histology on the outcome of bladder cancer
treated with curative intent. Urol Oncol. 27:3–7. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Scosyrev E, Ely BW, Messing EM, Speights
VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL,
Natale RB, et al: Do mixed histological features affect survival
benefit from neoadjuvant platinum-based combination chemotherapy in
patients with locally advanced bladder cancer? A secondary analysis
of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU
Int. 108:693–699. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Canvasser N, Weizer A, Crossley H, Dailey
S, He C, Kunju LP, Lee C, Hafez K, Hollenbeck B, Morgan T, Montie J
and Montgomery J: Micropapillary Differentiation Versus
Conventional Urothelial Carcinoma: Effects Of Neoadjuvant
Chemotherapy And Cystectomy On Survival. AUA 2014 conference.
abstract MP50-06.
|
|
59
|
Fernández MI, Williams SB, Willis DL,
Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo
CC, Czerniak BA, et al: Clinical risk stratification in patients
with surgically resectable micropapillary bladder cancer. BJU Int.
119:684–691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Schechter AL, Stern DF, Vaidyanathan L,
Decker SJ, Drebin JA, Greene MI and Weinberg RA: The neu oncogene:
An erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature.
312:513–516. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tschui J, Vassella E, Bandi N, Baumgartner
U, Genitsch V, Rotzer D, Seiler R, Thalmann GN and Fleischmann A:
Morphological and molecular characteristics of HER2 amplified
urothelial bladder cancer. Virchows Arch. 466:703–710. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zwick E, Bange J and Ullrich A: Receptor
tyrosine kinase signalling as a target for cancer intervention
strategies. Endocr Relat Cancer. 8:161–173. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wen XF, Yang G, Mao W, Thornton A, Liu J,
Bast RC Jr and Le XF: HER2 signaling modulates the equilibrium
between pro- and antiangiogenic factors via distinct pathways:
Implications for HER2-targeted antibody therapy. Oncogene.
25:6986–6996. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Scholl S, Beuzeboc P and Pouillart P:
Targeting HER2 in other tumor types. Ann Oncol. 12 Suppl 1:S81–S87.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hansel DE, Swain E, Dreicer R and Tubbs
RR: HER2 overexpression and amplification in urothelial carcinoma
of the bladder is associated with MYC coamplification in a subset
of cases. Am J Clin Pathol. 130:274–281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Eissa S, Ali HS, Al Tonsi AH, Zaglol A and
El Ahmady O: HER2/neu expression in bladder cancer: Relationship to
cell cycle kinetics. Clin Biochem. 38:142–148. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tolmachev V: Imaging of HER-2
overexpression in tumors for guiding therapy. Curr Pharm Des.
14:2999–3019. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Slamon DJ, Clark GM, Wong SG, Levin WJ,
Ullrich A and McGuire WL: Human breast cancer: Correlation of
relapse and survival with amplification of the HER-2/neu oncogene.
Science. 235:177–182. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gandour-Edwards R, Lara PN Jr, Folkins AK,
LaSalle JM, Beckett L, Li Y, Meyers FJ and DeVere-White R: Does
HER2/neu expression provide prognostic information in patients with
advanced urothelial carcinoma? Cancer. 95:1009–1015. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tinoco G, Warsch S, Glück S, Avancha K and
Montero AJ: Treating breast cancer in the 21st century: Emerging
biological therapies. J Cancer. 4:117–132. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs
H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M,
et al: Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Smyth EC and Cunningham D: Targeted
therapy for gastric cancer. Curr Treat Options Oncol. 13:377–389.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: ToGA Trial Investigators: Trastuzumab in combination with
chemotherapy versus chemotherapy alone for treatment of
HER2-positive gastric or gastro-oesophageal junction cancer (ToGA):
a phase 3 open-label randomised controlled trial. Lancet.
376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Laé M, Couturier J, Oudard S, Radvanyi F,
Beuzeboc P and Vieillefond A: Assessing HER2 gene amplification as
a potential target for therapy in invasive urothelial bladder
cancer with a standardized methodology: Results in 1005 patients.
Ann Oncol. 21:815–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Underwood M, Bartlett J, Reeves J,
Gardiner DS, Scott R and Cooke T: C-erbB-2 gene amplification: A
molecular marker in recurrent bladder tumors? Cancer Res.
55:2422–2430. 1995.PubMed/NCBI
|
|
77
|
Schraml P, Kononen J, Bubendorf L, Moch H,
Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP and Sauter G:
Tissue microarrays for gene amplification surveys in many different
tumor types. Clin Cancer Res. 5:1966–1975. 1999.PubMed/NCBI
|
|
78
|
Latif Z, Watters AD, Dunn I, Grigor K,
Underwood MA and Bartlett JM: HER2/neu gene amplification and
protein overexpression in G3 pT2 transitional cell carcinoma of the
bladder: A role for anti-HER2 therapy? Eur J Cancer. 40:56–63.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Ehsani L and Osunkoya AO: Human epidermal
growth factor receptor 2 expression in urothelial carcinoma of the
renal pelvis: Correlation with clinicopathologic parameters. Int J
Clin Exp Pathol. 7:2544–2550. 2014.PubMed/NCBI
|
|
80
|
Hussain MH, MacVicar GR, Petrylak DP, Dunn
RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM,
Trump DL, et al: National Cancer Institute: Trastuzumab,
paclitaxel, carboplatin, and gemcitabine in advanced human
epidermal growth factor receptor-2/neu-positive urothelial
carcinoma: Results of a multicenter phase II National Cancer
Institute trial. J Clin Oncol. 25:2218–2224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Caner V, Turk NS, Duzcan F, Tufan NL,
Kelten EC, Zencir S, Dodurga Y, Bagci H and Duzcan SE: No strong
association between HER-2/neu protein overexpression and gene
amplification in high-grade invasive urothelial carcinomas. Pathol
Oncol Res. 14:261–266. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Simonetti S, Russo R, Ciancia G, Altieri
V, De Rosa G and Insabato L: Role of polysomy 17 in transitional
cell carcinoma of the bladder: Immunohistochemical study of
HER2/neu expression and fish analysis of c-erbB-2 gene and
chromosome 17. Int J Surg Pathol. 17:198–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Li B, Kanamaru H, Noriki S, Fukuda M and
Okada K: Numeric aberration of chromosome 17 is strongly correlated
with p53 overexpression, tumor proliferation and histopathology in
human bladder cancer. Int J Urol. 5:317–323. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Inoue T, Sato K, Tsuchiya N, Matsuura S,
Iinuma M, Habuchi T and Kato T: Numeric aberrations of HER-2 and
chromosome 17 detected by fluorescence in situ hybridization in
urine-exfoliated cells from patients with urothelial carcinoma.
Urology. 64:617–621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Skagias L, Politi E, Karameris A,
Sambaziotis D, Archondakis A, Vasou O, Ntinis A, Michalopoulou F,
Moreas I, Koutselini H, et al: Prognostic impact of HER2/neu
protein in urothelial bladder cancer. Survival analysis of 80 cases
and an overview of almost 20 years' research. J BUON. 14:457–462.
2009.PubMed/NCBI
|
|
86
|
Sato K, Moriyama M, Mori S, Saito M,
Watanuki T, Terada K, Okuhara E, Akiyama T, Toyoshima K, Yamamoto
T, et al: An immunohistologic evaluation of C-erbB-2 gene product
in patients with urinary bladder carcinoma. Cancer. 70:2493–2498.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jimenez RE, Hussain M, Bianco FJ Jr,
Vaishampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr and
Grignon DJ: Her-2/neu overexpression in muscle-invasive urothelial
carcinoma of the bladder: Prognostic significance and comparative
analysis in primary and metastatic tumors. Clin Cancer Res.
7:2440–2447. 2001.PubMed/NCBI
|
|
88
|
Bolenz C, Shariat SF, Karakiewicz PI,
Ashfaq R, Ho R, Sagalowsky AI and Lotan Y: Human epidermal growth
factor receptor 2 expression status provides independent prognostic
information in patients with urothelial carcinoma of the urinary
bladder. BJU Int. 106:1216–1222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Naruse K, Yamada Y, Nakamura K, Aoki S,
Taki T, Zennami K, Katsuda R, Watanabe M, Nishikawa G, Itoh Y, et
al: Potential of molecular targeted therapy of HER-2 and Cox-2 for
invasive transitional cell carcinoma of the urinary bladder. Oncol
Rep. 23:1577–1583. 2010.PubMed/NCBI
|
|
90
|
Charfi S, Khabir A, Mnif H, Ellouze S,
Nabil Mhiri M and Boudawara-Sellami T: Immunohistochemical
expression of HER2 in urothelial bladder carcinoma and its
correlation with p53 and p63 expression. J Microsc Ultrastruct.
1:17–21. 2013. View Article : Google Scholar
|
|
91
|
Krüger S, Weitsch G, Büttner H,
Matthiensen A, Böhmer T, Marquardt T, Sayk F, Feller AC and Böhle
A: HER2 overexpression in muscle-invasive urothelial carcinoma of
the bladder: Prognostic implications. Int J Cancer. 102:514–518.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Li J, Jackson CL, Yang D, Noble L, Wheeler
M, MacKenzie D, Adegun T and Amin A: Comparison of tyrosine kinase
receptors HER2, EGFR, and VEGFR expression in micropapillary
urothelial carcinoma with invasive urothelial carcinoma. Target
Oncol. 10:355–363. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Kim B, Kim G, Song B, Lee C, Park JH and
Moon KC: HER2 protein over- expression and gene amplification in
plasmacytoid urothelial carcinoma of the urinary bladder. Dis
Markers. 6:20162016.
|
|
94
|
Miyama Y, Morikawa T, Nakagawa T, Homma Y
and Fukayama M: Lipid cell and micropapillary variants of
urothelial carcinoma of the ureter. Case Rep Oncol. 8:515–519.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Sauter G, Moch H, Moore D, Carroll P,
Kerschmann R, Chew K, Mihatsch MJ, Gudat F and Waldman F:
Heterogeneity of erbB-2 gene amplification in bladder cancer.
Cancer Res. 53:2199–2203. 1993.PubMed/NCBI
|
|
96
|
Coogan CL, Estrada CR, Kapur S and Bloom
KJ: HER-2/neu protein overexpression and gene amplification in
human transitional cell carcinoma of the bladder. Urology.
63:786–790. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Behzatoğlu K, Yörükoğlu K, Demir H and Bal
N: Human epidermal growth factor receptor 2 overexpression in
micropapillary and other variants of urothelial carcinoma. Eur Urol
Focus. Jun 21–2016.(Epub ahead of print).
|
|
98
|
Makise N, Morikawa T, Takeshima Y,
Fujimura T, Homma Y and Fukayama M: Urinary bladder urothelial
carcinoma with concurrent plasmacytoid and micropapillary
differentiations: A report of two cases with an emphasis on serum
carbohydrate antigen 19-9. Pathol Int. 65:495–500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Goodman AL and Osunkoya AO: Human
epidermal growth factor receptor 2 expression in micropapillary
urothelial carcinoma of the bladder: An analysis of 27 cases. Hum
Pathol. 57:160–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
El Ochi MR, Oukabli M, Bouaiti E, Chahdi
H, Boudhas A, Allaoui M, Ameur A, Abbar M and Al Bouzidi A:
Expression of human epidermal growth factor receptor 2 in bladder
urothelial carcinoma. BMC Clin Pathol. 17:32017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Kriegmair MC, Wirtz RM, Worst TS, Breyer
J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, et al:
Prognostic value of molecular breast cancer subtypes based on Her2,
ESR1, PGR and Ki67 mRNA-expression in muscle invasive bladder
cancer. Transl Oncol. 11:467–476. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American Society of Clinical Oncology/College of
American Pathologists clinical practice guideline focused update. J
Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Latif Z, Watters AD, Dunn I, Grigor KM,
Underwood MA and Bartlett JM: HER2/neu overexpression in the
development of muscle-invasive transitional cell carcinoma of the
bladder. Br J Cancer. 89:1305–1309. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Hynes NE and Stern DF: The biology of
erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta.
1198:165–184. 1994.PubMed/NCBI
|
|
105
|
Knowles MA and Hurst CD: Molecular biology
of bladder cancer: New insights into pathogenesis and clinical
diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ross JS, Wang K, Khaira D, Ali SM, Fisher
HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, et al:
Comprehensive genomic profiling of 295 cases of clinically advanced
urothelial carcinoma of the urinary bladder reveals a high
frequency of clinically relevant genomic alterations. Cancer.
122:702–711. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wülfing C, Machiels JP, Richel DJ, Grimm
MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F and
El-Hariry IA: A single-arm, multicenter, open-label phase 2 study
of lapatinib as the second-line treatment of patients with locally
advanced or metastatic transitional cell carcinoma. Cancer.
115:2881–2890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Mercogliano MF, Inurrigarro G, De Martino
M, Venturutti L, Rivas MA, Cordo-Russo R, Proietti CJ, Fernández
EA, Frahm I, Barchuk S, et al: Invasive micropapillary carcinoma of
the breast overexpresses MUC4 and is associated with poor outcome
to adjuvant trastuzumab in HER2-positive breast cancer. BMC Cancer.
17:8952017. View Article : Google Scholar : PubMed/NCBI
|
